SABCS® 2024 Scientific Session Abstract Title and Text Release and Embargo Policy

The abstract title and text release schedule is as follows:

• Regular and Late-Breaking Abstract titles will be published on our website as part of the program agenda at 4:30 p.m. CT on Friday, November 1, 2024.
• Regular and Late-Breaking Abstract text will be published at 4:30 p.m. CT on Monday, November 25, 2024.
• The submitting author will be notified if your abstract is selected to the official SABCS® press program. Apart from those selected for the press program, abstracts submitted to SABCS® are confidential and embargoed until they are published on the SABCS® website November 25, 2024. Embargoes on abstracts lift as soon as the abstracts are available online. To extend the Embargo to the start of your scheduled session email sabcs@uthscsa.edu.
• For more information on the press embargo policy please check out our Media web page.

Once an abstract is accepted for presentation, SABCS holds the copyright to the abstract.

Scientific session embargo requests

Any request for scientific session embargo not related to press or media should be sent to sabcs@uthscsa.edu by Monday, October 7.

Questions? Contact the symposium office at sabcs@uthscsa.edu or 210-450-1550. 

Confirmation of No Prior Publication/Presentation

Authors who submit an abstract confirm they have not previously published these data, they have not previously presented them at another scientific meeting, and that they are not planning to present or publish them prior to the dates of the SABCS® 2024. Preprints (draft research papers posted online before peer review) are not considered to be a prior publication if they are posted online before abstracts are submitted SABCS®. 

Abstracts submitted to SABCS® are confidential and embargoed until SABCS® publishes the abstracts.

Certain laws may require disclosure of clinical trial data through federal and international registries within a specific amount of time following trial completion, or disclosure of clinical trial data by federal and international agencies for regulatory purposes related to drug safety and efficacy. Such disclosures will not be considered a violation of the SABCS’s Embargo Policy, but the courtesy of advance notice to the SABCS® by email at SABCS@uthscsa.org is requested.   

Any other exceptions to this policy are at the discretion of SABCS® leadership.

Lobular Breast Cancer Research Abstract Merit Award

The Lobular Breast Cancer Alliance (LBCA) is excited to announce a new $5,000 sponsorship -  the Lobular Breast Cancer Research Abstract Merit Award, in collaboration with the American Association for Cancer Research (AACR). This merit award will recognize the best abstracts focusing on lobular breast cancer research among those selected for poster presentation at the 47th Annual San Antonio Breast Cancer Symposium (SABCS^®) held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, TX. 

Award submissions are no longer being accepted.

FAQS

What types of studies are considered for late-breaking abstracts?

• Abstracts detailing highly significant and timely findings in any area of breast cancer research, including clinical trials, that were not available at the time of the regular abstract deadline will be considered for presentation at the 2024 SABCS. Only those abstracts that are deemed to be of high scientific priority will be accepted.

May I present more than one abstract?

• There is no limit to the number of abstracts an author can submit and present, however authors are limited to one oral presentation at the SABCS®.

How many authors can be listed on an abstract?

• There is 50 author limit per abstract. 

When will I find out if my abstract has been accepted for presentation?

• Late September/Early October 2024: Decision Letters and Presentation Instructions will be emailed to the Presenting Author.

Can I present my accepted abstract at other venues?

• Authors who submit an abstract confirm they have not previously published these data, they have not previously presented them at another scientific meeting, and that they are not planning to present or publish them prior to the dates of the SABCS® 2024. Preprints (draft research papers posted online before peer review) are not considered to be a prior publication if they are posted online before abstracts are submitted SABCS®. Abstracts submitted to SABCS® are confidential and embargoed until SABCS® publishes the abstracts.
• Certain laws may require disclosure of clinical trial data through federal and international registries within a specific amount of time following trial completion, or disclosure of clinical trial data by federal and international agencies for regulatory purposes related to drug safety and efficacy. Such disclosures will not be considered a violation of the SABCS’s Embargo Policy, but the courtesy of advance notice to the SABCS® by email at SABCS@uthscsa.org is requested.
• Any other exceptions to this policy are at the discretion of SABCS® leadership.

If my abstract is accepted, what is the presentation format?

• Authors who are selected as the presenter of an abstract (at the time of submission) will be provided with instructions regarding the type of presentation to be made and the date and time of the presentation. For abstracts selected to be presented as posters, the SABCS will provide poster numbers and pushpins. For abstracts that are selected for short talks, slides must in 16:9 format and developed in PowerPoint.

Are there poster printing services available?

• Poster printing services are available for the SABCS®. Please continue to monitor our website for more information.

How do I reference an abstract in the conference proceedings?

• Abstracts that are printed in the SABCS® conference proceedings should be referenced as follows:

Author(s) of abstract.Title of abstract [abstract]. In: Name of conference or title of publication; conference dates; place of conference. place of publication: publisher; date of publication and abstract number.

Example:
Li TW, Jones PA. Methylation changes in early embryonic genes in cancer [abstract]. In: Proceedings of the 2024 San Antonio Breast Cancer Symposium; 2024 Dec 10-13; San Antonio, TX.; 2024. Abstract nr 30.

Since I transferred copyright to SABCS® when I submitted my abstract for publication in a conference Proceedings, can I re-use the text of my abstract that I submitted?

• Authors may reproduce the abstract - including tables - without requesting additional permission for the following:
  • In books, reviews, or subsequent research articles they write
  • To post a link to the online version of the abstract on their institutional website, if required by their institution
  • To submit a copy of their article to their university in support of a doctoral thesis.
• For all other purposes you must contact sabcs@uthscsa.edu to request permission to reuse the text of the abstract.